IL235450B - Myo-adhesive capsule containing total pullulan including formulation for filling a capsule containing a selective progesterone receptor influencing factor - Google Patents

Myo-adhesive capsule containing total pullulan including formulation for filling a capsule containing a selective progesterone receptor influencing factor

Info

Publication number
IL235450B
IL235450B IL235450A IL23545014A IL235450B IL 235450 B IL235450 B IL 235450B IL 235450 A IL235450 A IL 235450A IL 23545014 A IL23545014 A IL 23545014A IL 235450 B IL235450 B IL 235450B
Authority
IL
Israel
Prior art keywords
capsule
receptor modulator
progesterone receptor
mucoadhesive
fill formulation
Prior art date
Application number
IL235450A
Other languages
English (en)
Hebrew (he)
Other versions
IL235450A0 (en
Original Assignee
Allergan Pharmaceuticals Int Ltd
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL235450(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Pharmaceuticals Int Ltd, Repros Therapeutics Inc filed Critical Allergan Pharmaceuticals Int Ltd
Publication of IL235450A0 publication Critical patent/IL235450A0/en
Publication of IL235450B publication Critical patent/IL235450B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL235450A 2012-05-31 2014-11-02 Myo-adhesive capsule containing total pullulan including formulation for filling a capsule containing a selective progesterone receptor influencing factor IL235450B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653674P 2012-05-31 2012-05-31
PCT/US2013/043447 WO2013181449A1 (en) 2012-05-31 2013-05-30 Formulations and methods for vaginal delivery of antiprogestins

Publications (2)

Publication Number Publication Date
IL235450A0 IL235450A0 (en) 2014-12-31
IL235450B true IL235450B (en) 2020-02-27

Family

ID=48614182

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235450A IL235450B (en) 2012-05-31 2014-11-02 Myo-adhesive capsule containing total pullulan including formulation for filling a capsule containing a selective progesterone receptor influencing factor

Country Status (22)

Country Link
US (1) US10328022B2 (cg-RX-API-DMAC7.html)
EP (1) EP2854763B1 (cg-RX-API-DMAC7.html)
JP (1) JP6341910B2 (cg-RX-API-DMAC7.html)
KR (1) KR102127348B1 (cg-RX-API-DMAC7.html)
CN (1) CN104334158B (cg-RX-API-DMAC7.html)
AU (1) AU2013267359C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014029131B1 (cg-RX-API-DMAC7.html)
CA (1) CA2872644A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014003232A1 (cg-RX-API-DMAC7.html)
CO (1) CO7141411A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140567A (cg-RX-API-DMAC7.html)
EA (1) EA030444B1 (cg-RX-API-DMAC7.html)
ES (1) ES2701400T3 (cg-RX-API-DMAC7.html)
IL (1) IL235450B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10548A (cg-RX-API-DMAC7.html)
MX (2) MX363640B (cg-RX-API-DMAC7.html)
NZ (1) NZ702467A (cg-RX-API-DMAC7.html)
PH (1) PH12014502516B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201704858PA (cg-RX-API-DMAC7.html)
UA (1) UA114106C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013181449A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408262B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX384159B (es) * 2014-05-05 2025-03-14 Repros Therapeutics Inc Formulaciones y métodos para el suministro vaginal de antiprogestinas.
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US11623008B2 (en) 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
JP2017531026A (ja) * 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
EP3025709B1 (en) 2014-11-27 2020-09-30 Capsugel Belgium NV Dosage form articles for external mucosal applications
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
BR112019021396A2 (pt) 2017-04-14 2020-04-28 Capsugel Belgium Nv processo para fabricação de pululano
AU2018251256B2 (en) * 2017-04-14 2023-10-05 Capsugel Belgium Nv Pullulan capsules

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP0806952B1 (de) 1995-02-02 2003-04-02 Schering Aktiengesellschaft Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
GB9522403D0 (en) * 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
EP0900234B1 (en) 1996-05-01 2000-07-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
CA2403756C (en) * 2000-03-17 2010-02-09 Hyun K. Kim Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IN191020B (cg-RX-API-DMAC7.html) 2000-03-28 2003-09-13 Dabur Res Foundation
AU1824302A (en) 2000-10-18 2002-04-29 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
WO2003005954A2 (en) 2001-07-09 2003-01-23 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
WO2003020210A2 (en) 2001-08-29 2003-03-13 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
JP2003143474A (ja) 2001-11-02 2003-05-16 Matsushita Electric Ind Co Ltd 映像信号処理システム
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
NZ552720A (en) 2004-07-09 2010-02-26 Population Council Inc Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AU2006227243B2 (en) 2005-03-22 2011-10-27 Allergan pharmaceuticals International Ltd. Dosing regimes for trans-clomiphene
JP2008536910A (ja) 2005-04-20 2008-09-11 ファイザー・リミテッド プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体
DE102005030294A1 (de) 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
EP1940413A1 (en) * 2005-09-29 2008-07-09 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
CN1846703A (zh) 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
US8173626B2 (en) 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
KR20070116538A (ko) * 2006-06-05 2007-12-10 유겐가이샤 코리츠 쇼지 삽입 보조 기구
JP2008012281A (ja) * 2006-06-05 2008-01-24 Koritsu Shoji:Kk 挿入補助器具
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CA2673128C (en) 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
JP5379121B2 (ja) * 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
US8569274B2 (en) 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
JP5555631B2 (ja) 2007-09-20 2014-07-23 ラピドット メディカル インポート アンド マーケティング リミテッド ミフェプリストンによる子宮平滑筋腫、平滑筋腫、筋腫、子宮類線維腫、子宮内膜症、または腺筋症を治療するための組成物および手段
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
JP5992330B2 (ja) * 2009-09-29 2016-09-14 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 物質を投与するための子宮内電子カプセル
UA113283C2 (xx) 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
WO2012121767A1 (en) 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування

Also Published As

Publication number Publication date
BR112014029131A2 (pt) 2018-05-29
CL2014003232A1 (es) 2015-03-13
CN104334158B (zh) 2018-08-10
AU2013267359C1 (en) 2016-09-29
JP6341910B2 (ja) 2018-06-13
EP2854763B1 (en) 2018-09-26
PH12014502516A1 (en) 2015-01-12
IN2014DN10548A (cg-RX-API-DMAC7.html) 2015-08-21
MX2014014054A (es) 2015-02-12
MX382986B (es) 2025-03-13
EP2854763A1 (en) 2015-04-08
PH12014502516B1 (en) 2015-01-12
JP2015518052A (ja) 2015-06-25
SG11201407397WA (en) 2014-12-30
MX363640B (es) 2019-03-28
ES2701400T3 (es) 2019-02-22
AU2013267359B2 (en) 2016-05-26
SG10201704858PA (en) 2017-07-28
UA114106C2 (xx) 2017-04-25
WO2013181449A1 (en) 2013-12-05
IL235450A0 (en) 2014-12-31
BR112014029131B1 (pt) 2021-03-09
AU2013267359A1 (en) 2014-11-20
EA030444B1 (ru) 2018-08-31
US10328022B2 (en) 2019-06-25
CO7141411A2 (es) 2014-12-12
CA2872644A1 (en) 2013-12-05
ZA201408262B (en) 2015-12-23
KR102127348B1 (ko) 2020-06-29
NZ702467A (en) 2016-07-29
US20150111862A1 (en) 2015-04-23
CN104334158A (zh) 2015-02-04
HK1206622A1 (en) 2016-01-15
KR20150014928A (ko) 2015-02-09
MX2019003467A (es) 2019-06-06
CR20140567A (es) 2015-03-09
EA201492290A1 (ru) 2015-03-31

Similar Documents

Publication Publication Date Title
IL235450B (en) Myo-adhesive capsule containing total pullulan including formulation for filling a capsule containing a selective progesterone receptor influencing factor
AP3338A (en) Glucagon receptor modulator
IL237277A0 (en) Compositions of an antibody to the anti-prolactin receptor
IL228422A0 (en) Hormone nuclear protein modulators
EP2909096A4 (en) DISPOSABLE DISPENSER PACKAGE
EP2862558A4 (en) DEVICE FOR FILLING A MEDICINAL PRODUCT
SG11201401794YA (en) Selective androgen receptor modulators
PL2748105T3 (pl) Urządzenie napełniające
ZA201500096B (en) Indolecarbonitriles as selective androgen receptor modulators
EP2851059A4 (en) DEVICE FOR FILLING A MEDICAL AGENT
IL239076B (en) Modulators and selective androgen receptor
GB2498796B (en) Pill dispensing device
GB2498216B (en) Bag filling
SI2968351T1 (sl) Bispecifična protitelesa EGFR/C-MET
EP2935284A4 (en) HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
LT2916823T (lt) Ko-mikronizacijos produktas, apimantis progesterono receptoriaus selektyvų moduliatorių
EP2892527A4 (en) HETEROCYCLIC MODULATORS OF NUCLEAR HORMONAL RECEPTORS
PL2917128T3 (pl) Urządzenie do dozowania kremów
PL2861083T3 (pl) Pakowana luzem, niepowlekana guma do żucia
SG11201406097SA (en) Capsule formulation
GB201213312D0 (en) Packaged chewing gum
GB201306268D0 (en) Chewing gum dispenser
GB201208190D0 (en) Anti over fill device
GB201114944D0 (en) Filling device
GB201203469D0 (en) Fill valve adn sanitary device

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed